Effects of cannabis use on outcomes of psychotic disorders: Systematic review

British Journal of Psychiatry

Volumn 193, Issue 5, 2008, Pages 357-363

  Zammit, Stanley ^a,b   Moore, Theresa H M ^a   Lingford Hughes, Anne ^a   Barnes, Thomas R E ^c   Jones, Peter B ^d   Burke, Margaret ^a   Lewis, Glyn ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

CLINICAL PRACTICE; DATA BASE; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; HOSPITAL READMISSION; HUMAN; LONGITUDINAL STUDY; METHODOLOGY; OUTCOME ASSESSMENT; PSYCHOSIS; QUALITY CONTROL; RELAPSE; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; HUMANS; MARIJUANA ABUSE; PSYCHOTIC DISORDERS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 55949128528     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.107.046375     Document Type: Review

References (34)

1. Hall W, Degenhardt L. Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust N Z J Psychiatry 2000; 34: 26-34.
2. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594-608.
3. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol 2004; 29: 1558-72.
4. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996; 42: 201-7.
5. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28.
6. Dixon L, Haas G, Weiden P, Sweeney J, Frances A. Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients' self-reports. Schizophr Bull 1990; 16: 69-79.
7. Schofield D, Tennant C, Nash L, Degenhardt L, Cornish A, Hobbs C, Brennan G. Reasons for cannabis use in psychosis. Aust N Z J Psychiatry 2006; 40: 570-4.
8. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005; 100: 612-8.
9. Hides L, Dawe S, Kavanagh DJ, Young McD R. A prospective study of psychotic symptom and cannabis relapse in recent onset psychosis. Br J Psychiatry 2006; 189: 137-43.
10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
11. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006; 189: 229-34.
12. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Res 2005; 133: 35-43.
13. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286-90.
14. Grech A, van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry: 20: 349-53.
15. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res 2005; 75: 135-7.
16. Green AI, Tonen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004; 66: 125-35.
17. Martinez-Arevalo MJ, Calcedo-Ordonez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 1994; 164: 679-81.
18. Arango C, Calcedo BA, Gonzalez S, Calcedo OA. Violence in inpatients with schizophrenia: a prospective study. Schizophr Bull 1999; 25: 493-503.
19. Arias Horcajadas F, Romero SS, Calo JJP. Relevance of drug use in clinical manifestations of schizophrenia [Spanish]. Actas Esp Psiquiatr 2002; 30: 65-73.
20. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999; 249: 45-9.
21. Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall W, McKay D. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med 2007; 37: 1-8.
22. Grace RF, Shenfield G, Tennant C. Cannabis and psychosis in acute psychiatric admissions. Drug Alcohol Rev 2000; 19: 287-90.
23. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta psychiatr Scand 2007; 115: 304-9.
24. Arseneault L, Moffitt TE, Caspi A, Taylor PJ, Silva PA. Mental disorders and violence in a total birth cohort: results from the Dunedin Study. Arch Gen Psychiatry 2000; 57: 979-86.
25. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-9.
26. Linszen DH, Dingemans PM, Nugter MA, Van der Does AJ, Scholte WF, Lenior MA. Patient attributes and expressed emotion as risk factors for psychotic relapse. Schizophr Bull 1997; 23: 119-30.
27. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003; 28: 48-54.
28. Lauronen E, Miettunen J, Veijola J, Karhu M, Jones PB, Isohanni M. Outcome and its predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Eur Psychiatry 2007; 22: 129-36.
29. Munk-Jorgensen P, Mortensen PB. Social outcome in schizophrenia: a 13-year follow-up. Soc Psychiatry Psychiatr Epidemiol 1992; 27: 129-34.
30. Hofler M, Lieb R, Perkonigg A, Schuster P, Sonntag H, Wittchen HU. Covariates of cannabis use progression in a representative population sample of adolescents: a prospective examination of vulnerability and risk factors. Addiction 1999; 94: 1679-94.
31. von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend 2002; 68: 49-64.
32. Jane-Llopis E, Matytsina I. Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug Alcohol Rev 2006; 25: 515-36.
33. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-8.
34. Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand 1992; 85: 48-55.